help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on March 1, 2005
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1995
A more recent version of this article appeared on May 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/5/2888    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cabassi, A.
Right arrow Articles by Fiaccadori, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cabassi, A.
Right arrow Articles by Fiaccadori, E.

Submitted on October 11, 2004
Accepted on February 18, 2005

Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat

Aderville Cabassi*, Pietro Coghi, Paolo Govoni, Elisa Barouhiel, Ester Speroni, Stefania Cavazzini, Anna Maria Cantoni, Renato Scandroglio, and Enrico Fiaccadori

Laboratory of Clinical Physiology, Hypertension Unit (A.C.,P.C.,E.B.,E.F.) and Toxicology Unit (S.C.), Department of Internal Medicine, Nephrology and Health Sciences; Section of Histology and Embryology, Department of Experimental Medicine (P.G.,R.S.), University of Parma Faculty of Medicine, Via Gramsci 14, 43100 Parma, Veterinary Pathology Unit (A.M.C.), Department of Animal Health, University of Parma Faculty of Veterinary Medicine Via del Taglio 10, 43100 Parma Italy; Department of Pharmacology (E.S.), Faculty of Pharmacy, University of Bologna, Via Irnerio 48, Bologna, Italy

* To whom correspondence should be addressed. E-mail: cabassia{at}unipr.it.

Advanced heart failure is characterized by increased activation of the renin-angiotensin system and the development of cachexia. Angiotensin II has been proposed as a lipid metabolism regulator. The effects of exogenous angiotensin II (osmotic mini-pump, 525 ng/kg/min for 12 days) on interstitial sc glycerol and norepinephrine levels, indexes of lipolysis and sympathetic activation respectively, were measured in Sprague Dawley rats by consecutive microdialysis performed in vivo in white adipose tissue. Higher sustained interstitial glycerol and norepinephrine levels were found after 7 and 12 days of Ang II infusion. Triglyceride/DNA content ratio and adipocyte diameter were reduced in sc and visceral (retroperitoneal and epididymal) fat tissues of angiotensin II-infused rats, whose body weight was lower and blood pressure higher. Losartan, an angiotensin II-receptor1 blocker, and carvedilol, an alpha1-non-selective-beta1,2,3-adrenergic blocker, but not doxazosin, an alpha1-selective-adrenergic blocker, lowered glycerol and norepinephrine levels, preventing lipolysis and weight loss. Our results indicate that angiotensin II stimulates lipolysis in sc and visceral adipocytes by sympathetic activation and {beta}-adrenergic-receptor stimulation. Non-selective-{beta}-adrenergic and angiotensin II-receptor1 blockade markedly attenuated the rise of norepinephrine, preventing catabolic effects. The metabolic benefits of carvedilol and losartan, in addition to recognized protective cardiovascular effects, may be relevant in cachectic patients with advanced heart failure.
Key words: Angiotensin II • sympathetic activity • norepinephrine • glycerol • hormone sensitive lipase • subcutaneous and visceral fat • microdialysis • cachexia • alpha-adrenergic • beta-adrenergic blockade




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet
Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Boschmann, S. Engeli, F. Adams, G. Franke, F. C. Luft, A. M. Sharma, and J. Jordan
Influences of AT1 receptor blockade on tissue metabolism in obese men
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R219 - R223.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society